Back

Cardiorenal effects and safety of initiation of empagliflozin after acute myocardial infarction

1 September 2024 (09:00 - 09:11)
Organised by: Logo
Congress Presentation Part of: Smaller trials, trial updates, and other studies on coronary artery disease Pharmacotherapy ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Professor Deepak Bhatt

Icahn School of Medicine at Mount Sinai, New York City (United States of America)

7 More presentations in this session

Presentation thumbnail
Effects of Beta-Blockers on Quality of Life and Well-being in Patients with Myocardial Infarction and Preserved Left Ventricular Function - a prespecified substudy from REDUCE-AMI
Associate Professor R. Hofmann (Stockholm, SE)
Slides Video
Presentation thumbnail
Short- and long-term effects of beta-blockers on symptoms of anxiety and depression in patients with myocardial infarction and preserved left ventricular function: prespecified substudy from REDUCE-AM
Mr P. Leissner (Uppsala, SE)
Slides Video
Presentation thumbnail
Coronary computed tomography angiography guided management of patients with stable chest pain: 10-year outcomes from the SCOT-HEART trial
Professor M. Williams (Edinburgh, GB)
Slides Video
Presentation thumbnail
Adherence to Nordic and Mediterranean dietary patterns may be associated with a lower absolute risk of incident atherosclerotic cardiovascular disease
Doctor C. Bork (Aalborg, DK)
Slides Video
Presentation thumbnail
Cardiovascular Risk Scoring or CT Angiography for Lifestyle and Risk Factor Modification in Primary Prevention of Cardiovascular Disease The SCOT-HEART 2 IMPACT Study
Doctor M. Mcdermott (Edinburgh, GB)
Slides Video

Access the full session

Session thumbnail
Smaller trials, trial updates, and other studies on coronary artery disease
Video

The Event

Event poster

ESC Congress 2024

1 September 2024 09:00 CET
You may be interested in
thumbnail
Congress Presentation
The effect of empagliflozin after acute myocardial infarction in patients with and without diabetes: a pre-specified analysis of the EMPACT-MI trial
thumbnail
Congress Presentation
Where do we stand with SGLT2i post-myocardial infarction?
thumbnail
Congress Presentation
Renal function in patients with acute decompensated de novo heart failure treated with the SGLT2 inhibitor empagliflozin: a secondary analysis of the EMPAG-HF trial

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources